Resistance is futile
The Antimicrobial Resistance crisis demands different thinking.
By breaking with tradition, we found a new way forward.
Antibiotics added 23 years to the human lifespan.
Humanity is not ready to lose them.
Antimicrobial resistance (AMR) means that microbes have developed the ability to overcome the treatments that used to kill them.
THE ROCK
Antibiotics are life savers
Good bacteria are crucial for our health. Unfortunately, a handful of bad bacteria (pathogenic) can rapidly escalate into debilitating disease, death or limb amputations. Antibiotics are unique drugs that actually cure disease and are the foundation of modern medicine.
THE HARD PLACE
Antibiotics accelerate AMR
Bacteria are constantly evolving, and put selection pressure on both good and bad bacteria. The more we use antibiotics, the faster resistance spreads. Since 2024, resistance to last-resort antibiotics has risen by 35%. Also, Pan-Drug Resistance appeared for the first time, i.e. bacteria for which there is no treatment.
It is time to draw the line here.
10 million people are projected to die from AMR annually by 2050.
What if resistance could be switched off ?
For decades, the response to AMR has focused on finding stronger antibiotics to treat rising resistance, which has resulted in a reactive arms race with no end in sight.
Lixa chose a different path. By focusing our research on resistance per se, we found a new control point in microbial biology with the potential to switch resistance off. This tames multi-drug resistant planktonic and biofilm bacteria and restores the effectiveness of already existing antibiotics, biocides or other antimicrobial treatments.
Lixa’s technology represents a novel category of treatment. One that is scalable across human health, industrial systems, shipping and agribusiness.
One control point that leads to every antimicrobial working as intended.
NeoX™, resistance- breaking at its core.
Built with human health as our priority and designed to work across every environment where resistance takes hold.
NeoX™ addresses AMR at its source, not by overpowering bacteria, but by switching off the ability to action "resistance." The result is a proprietary platform technology for deployment across infection types, species, borders and industries.
Designed for
clinical impact.
Built for scale.
Aligned with global regulatory priorities.
Hope, with a plan. Built with grit.
